维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="OSSENKOPPELE J"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel,on behalf of the European LeukemiaNet显示文摘	Dhner H Estey EH Amadori S Appelbaum FR Büchner T Burnett AK Dombret H Fenaux P Grimwade D Larson RA Lo-Coco F Naoe T Niederwieser D Ossenkoppele GJ Sanz MA Sierra J Tallman MS Lwenberg B Bloomfield CD	2010	{H}Blood2010，，03：	1
2	The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients显示文摘	OSSENKOPPELE J GRAVELAND W J SONNEVELD P	2004	Blood2004，103，8：	1
3	Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications显示文摘	VAN DE LOOSDRECHT A A HUIJGENS P C OSSENKOPPELE G J	2004	Anti Cancer Drugs2004，15，：	1
4	ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination显示文摘	Berge R L Oudejans J J Ossenkoppele G J	2000	Clin Pathol2000，53，6：	1
5	ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination显示文摘	Berge R L Oudejans J J Ossenkoppele G J	2000	Clin Pathol2000，53，6：	1
6	ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination显示文摘	ten BERGE R L OUDEJANS J J OSSENKOPPELE G J	2000	J Clin Pathol2000，53，：	1
7	The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients显示文摘	OSSENKOPPELE G J GRAVELAND W J SONNEVELD P	2004	Blood2004，103，8：	1
8	Improved risk stratifiction by the integration of therevised International Prognostic Scoring System withthe Myelodysplastic Syndrome Comorbidity Index 显示文摘	van Spronaen M F Ossenkoppele G J Holman R etal	2014	European Journal of Cancer2014，50，18：	1
9	The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients 显示文摘	Ossenkoppele GJ Graveland W J Sonneveld P	2004	Blood2004，103，8：	1
10	High-dose daunorubicin in older pa- tients with acute myeloid leukemia显示文摘	LOWENBERG B OSSENKOPPELE G J VAN PUTTEN W	2009	N Engl J Med2009，361，：	1
11	The value of fiudarabine in addition to ARA-C and G,-CSF in the treatment of patients with high-risk myelodysplastie syndromes and AML in elderly patients显示文摘	Ossenkoppele G J Graveland W J Sonneveld P	2004	Blood2004，103，8：	1
12	Treatment of multiple myeloma in elderly patients new developments显示文摘	Ossenkoppele G J	1997	Drugs Aging1997，11，2：	1
13	The value of fludarabine in addition to ARA - C and G-CSF in the treatment of patients with high - risk myelodysp lastic syndromes and AML in elderly patients 显示文摘	OSSENKOPPELE G J GRAVELAND W J SONNEVELD P etal	2004	Blood2004，103，8：	1
14	Early treatment response in malignant lymphoma, as determined by planar fluorine- 18-fluorodeoxyglucose seintigraphy 显示文摘	Hoekstra OS Ossenkoppele C J Golding R	1993	J Nuel Med1993，34，10：	1
15	Review of the relevance of aberrant antigen expression by flow cytometin mycloid neoplasms 显示文摘	Ossenkoppele G J van de Loosdrecht AA Schuurhuis GJ	2011	Br J Haematol2011，153，4：	1
16	Differences of cellular composition and adhesion molecule expression in 'leukemic'as compared with ' normal' human long-term bone marrow cultures显示文摘	DENKERS I A BEELEN R H OSSENKOPPELE G J	1992	Ann Hematol1992，64，5：	1
17	High- dose daunorubicin in older patients with acute myeloid leukemia显示文摘	Lowenberg B Ossenkoppele G J van Putten W	2009	N Engl J Med2009，361，13：	1
18	High-dose daunorubicin in older patients with acute myeloid leukemia显示文摘	BOB L GERT J OSSENKOPPEL E	2009	N Engl J Med2009，361，：	1
19	Leukemia-derived dendritic cells: towards clinical vac cination protocols in acute myeloid leukemia 显示文摘	Houtenbos I Westers TM Ossenkoppele G J	2006	Haematologica2006，91，3：	1
20	Results from the ENEST-nd extension study:efficacy and safety of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP),treated with nilotinib 400mg twice daily(BID) after suboptimal response(SoR) or treatment failure(TF) to imatinib 400 mg once daily(QD) or nilotinib 300mg BID显示文摘	Hochhaus A Ossenkoppele G Reiffers J	2011	Blood2011，118，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示